Personalis Inc (NAS:PSNL)

$ 5.87 -0.39 (-6.23%) Market Cap: 497.15 Mil Enterprise Value: 398.65 Mil PE Ratio: 0 PB Ratio: 2.49 GF Score: 61/100

Q3 2024 Personalis Inc Earnings Call Transcript
Nov 06, 2024

$5.58 (-1.06%)

Earnings
Q2 2024 Personalis Inc Earnings Call Transcript
Aug 07, 2024

$2.88 (-10.00%)

Earnings
Q1 2024 Personalis Inc Earnings Call Transcript
May 08, 2024

$1.57 (-0.95%)

Earnings
Q4 2023 Personalis Inc Earnings Call Transcript
Feb 28, 2024

$1.46 (-2.67%)

Earnings
Q3 2023 Personalis Inc Earnings Call Transcript
Nov 07, 2023

$0.9628 (-9.17%)

Earnings
Personalis Inc Clinical Update Call Transcript
Oct 24, 2023
Q2 2023 Personalis Inc Earnings Call Transcript
Aug 08, 2023

$1.98 (+4.21%)

Earnings
Q1 2023 Personalis Inc Earnings Call Transcript
May 03, 2023

$2.42 (+10.00%)

Earnings
Q4 2022 Personalis Inc Earnings Call Transcript
Feb 23, 2023

$3.18

Earnings
Q3 2022 Personalis Inc Earnings Call Transcript
Nov 02, 2022

$2.7 (-1.46%)

Earnings
Q2 2022 Personalis Inc Earnings Call Transcript
Aug 03, 2022

$4.48 (+10.07%)

Earnings
Personalis Inc at UBS Global Healthcare Conference Transcript
May 24, 2022
Q1 2022 Personalis Inc Earnings Call Transcript
May 04, 2022

$5.97 (+2.93%)

Earnings
Q4 2021 Personalis Inc Earnings Call Transcript
Feb 24, 2022

$10.04 (+9.61%)

Earnings
Q3 2021 Personalis Inc Earnings Call Transcript
Nov 04, 2021

$21.25 (+6.04%)

Earnings
Personalis Inc Business Update Call Transcript
Sep 20, 2021
Personalis Inc at Morgan Stanley Global Healthcare Conference (Virtual) Transcript
Sep 09, 2021
Q2 2021 Personalis Inc Earnings Call Transcript
Aug 04, 2021

$20.23 (+1.35%)

Earnings
Personalis Inc Annual Shareholders Meeting Transcript
May 14, 2021
Q1 2021 Personalis Inc Earnings Call Transcript
May 05, 2021

$21.04 (-2.77%)

Earnings
Q4 2020 Personalis Inc Earnings Call Transcript
Feb 25, 2021

$31.68 (-8.68%)

Earnings
Q3 2020 Personalis Inc Earnings Call Transcript
Nov 05, 2020

$26.77 (+1.48%)

Earnings
Personalis Inc at Morgan Stanley Global Healthcare Conference (Virtual) Transcript
Sep 17, 2020
Q2 2020 Personalis Inc Earnings Call Transcript
Aug 06, 2020

$21.66 (-1.63%)

Earnings
Personalis Inc at UBS Global Healthcare Conference (Virtual) Transcript
May 19, 2020
Personalis Inc Annual Shareholders Meeting Transcript
May 15, 2020
Q1 2020 Personalis Inc Earnings Call Transcript
May 07, 2020

$10.34 (-1.15%)

Earnings
Q4 2019 Personalis Inc Earnings Call Transcript
Mar 25, 2020

$7 (+7.53%)

Earnings
Q3 2019 Personalis Inc Earnings Call Transcript
Nov 13, 2019

$10.89 (+6.97%)

Earnings
Q2 2019 Personalis Inc Earnings Call Transcript
Aug 13, 2019

$19.71 (+2.39%)

Earnings

Personalis Inc Clinical Update Call Transcript

Oct 24, 2023 / 01:00PM GMT

Release Date Price: $1.07 (+15.04%)

Transcript 10-Q8-K

Operator

Greetings, and welcome to Personalis Clinical Update Call. (Operator Instructions) As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Rich Chen, Chief Medical Officer and EVP of R&D. Thank you, Mr. Chen.

Richard Chen

Personalis, Inc. - Executive VP of R&D and Chief Medical Officer

Good morning, everyone, and welcome to our webinar today. I'm Richard Chen, Chief Medical Officer and EVP of R&D of Personalis. Also here is our CEO, Chris Hall; and our CFO, Aaron Tachibana. We are absolutely thrilled to be joined today by Dr. Charlie Swanton, Cancer Research UK's Chief Clinician and Professor at the Francis Crick Institute, world renowned for his pioneering work in cancer genomics and cancer evolution.

Dr. Swanton has graciously agreed to walk us through new exciting results from their groundbreaking TRACERx lung cancer study where they use our next personal test for cancer detection. And this data was just presented a few days ago at the ESMO Conference in Madrid. So before turning it over to

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.